Willow Biosciences Inc (WLLW) - Total Assets

Latest as of March 2025: CA$2.31 Million CAD ≈ $1.67 Million USD

Based on the latest financial reports, Willow Biosciences Inc (WLLW) holds total assets worth CA$2.31 Million CAD (≈ $1.67 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Willow Biosciences Inc net assets for net asset value and shareholders' equity analysis.

Willow Biosciences Inc - Total Assets Trend (2000–2024)

This chart illustrates how Willow Biosciences Inc's total assets have evolved over time, based on quarterly financial data.

Willow Biosciences Inc - Asset Composition Analysis

Current Asset Composition (December 2024)

Willow Biosciences Inc's total assets of CA$2.31 Million consist of 26.4% current assets and 73.6% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 13.4%
Accounts Receivable CA$39.00K 1.6%
Inventory CA$56.00K 2.3%
Property, Plant & Equipment CA$0.00 0.0%
Intangible Assets CA$0.00 0.0%
Goodwill CA$0.00 0.0%

Asset Composition Trend (2000–2024)

This chart illustrates how Willow Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see WLLW market cap.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Willow Biosciences Inc's current assets represent 26.4% of total assets in 2024, a decrease from 100.0% in 2000.
  • Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 0.1% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
  • Asset Diversification: The largest asset category is inventory at 2.3% of total assets.

Willow Biosciences Inc Competitors by Total Assets

Key competitors of Willow Biosciences Inc based on total assets are shown below.

Company Country Total Assets
Daihan Pharmaceutical Co.Ltd
KQ:023910
Korea ₩344.02 Billion
Aurobindo Pharma Limited
NSE:AUROPHARMA
India Rs525.46 Billion
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
China CN¥56.56 Billion
Ningbo Menovo Pharm Co Ltd
SHG:603538
China CN¥4.75 Billion
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
China CN¥7.26 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
China CN¥1.69 Billion
Hainan Honz Pharmaceutical Co
SHE:300086
China CN¥1.88 Billion

Willow Biosciences Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.01 1.42 9.12
Quick Ratio 1.01 1.29 8.97
Cash Ratio 0.00 0.00 0.00
Working Capital CA$17.00K CA$702.00K CA$12.22 Million

Willow Biosciences Inc - Advanced Valuation Insights

This section examines the relationship between Willow Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 9.89
Latest Market Cap to Assets Ratio 2.07
Asset Growth Rate (YoY) -62.7%
Total Assets CA$2.49 Million
Market Capitalization $5.15 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Willow Biosciences Inc's assets at a significant premium (2.07x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Willow Biosciences Inc's assets decreased by 62.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Willow Biosciences Inc (2000–2024)

The table below shows the annual total assets of Willow Biosciences Inc from 2000 to 2024.

Year Total Assets Change
2024-12-31 CA$2.49 Million
≈ $1.80 Million
-62.70%
2023-12-31 CA$6.67 Million
≈ $4.83 Million
-63.23%
2022-12-31 CA$18.15 Million
≈ $13.13 Million
-48.17%
2021-12-31 CA$35.02 Million
≈ $25.33 Million
+60.15%
2020-12-31 CA$21.86 Million
≈ $15.82 Million
-35.47%
2019-12-31 CA$33.88 Million
≈ $24.51 Million
+3403.87%
2018-12-31 CA$967.03K
≈ $699.54K
+33.53%
2017-12-31 CA$724.18K
≈ $523.86K
-57.39%
2016-12-31 CA$1.70 Million
≈ $1.23 Million
-29.64%
2015-12-31 CA$2.42 Million
≈ $1.75 Million
-0.55%
2014-12-31 CA$2.43 Million
≈ $1.76 Million
+1.79%
2013-12-31 CA$2.39 Million
≈ $1.73 Million
+11.65%
2012-12-31 CA$2.14 Million
≈ $1.55 Million
-29.74%
2011-12-31 CA$3.04 Million
≈ $2.20 Million
-18.37%
2010-12-31 CA$3.73 Million
≈ $2.70 Million
-33.03%
2009-12-31 CA$5.56 Million
≈ $4.02 Million
+27.20%
2008-12-31 CA$4.37 Million
≈ $3.16 Million
+42.36%
2007-12-31 CA$3.07 Million
≈ $2.22 Million
+394.02%
2006-12-31 CA$621.91K
≈ $449.88K
+31.68%
2005-12-31 CA$472.29K
≈ $341.65K
+44455.66%
2004-12-31 CA$1.06K
≈ $766.79
-98.90%
2002-12-31 CA$96.40K
≈ $69.74K
-2.90%
2001-12-31 CA$99.28K
≈ $71.81K
-9.61%
2000-12-31 CA$109.83K
≈ $79.45K
--

About Willow Biosciences Inc

TO:WLLW Canada Drug Manufacturers - Specialty & Generic
Market Cap
$18.10 Million
CA$25.02 Million CAD
Market Cap Rank
#28310 Global
#1281 in Canada
Share Price
CA$0.17
Change (1 day)
+0.00%
52-Week Range
CA$0.01 - CA$0.32
All Time High
CA$2.08
About

Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 20… Read more